Download full-text PDF |
Source |
---|
Parasite Epidemiol Control
February 2025
Parasites and Vector Biology Research Unit (PAVBRU), Department of Microbiology and Parasitology, University of Buea, Buea, Cameroon.
Background: Parasitic infections are known to suppress the cell mediated immunity that protects against tuberculosis. The status of parasitic infections among bacteriologically confirmed tuberculosis patients and their household contacts in Cameroon is not well established. This study aimed at reporting the status of parasitic infections in TB patients and their household contacts with keen interest in associated risk factors to disease exposure.
View Article and Find Full Text PDFNarra J
December 2024
Department of Clinical Pathology, Faculty of Medicine, Universitas Trisakti, Jakarta, Indonesia.
Successfully treating tuberculosis (TB) could significantly help reduce its spread. The aim of this study was to identify factors associated with successful TB treatment. A retrospective study was conducted in West Nusa Tenggara, Indonesia, using data from the National TB Information System (SITB) covering patients from January 1 to December 31, 2022.
View Article and Find Full Text PDFEClinicalMedicine
January 2025
School of Epidemiology and Public Health, University of Ottawa, Ottawa, Canada.
Background: Targeted next-generation sequencing (tNGS) is promising alternative to phenotypic drug susceptibility testing (pDST) for detecting drug-resistant tuberculosis (DRTB). This study explored the potential cost-effectiveness of tNGS for the diagnosis of DR-TB across 3 settings: India, South Africa and Georgia.
Methods: To inform WHO guideline development group (GDG) on tNGS we developed a stochastic decision analysis model and assessed cost-effectiveness of tNGS for DST among rifampicin resistance individuals.
medRxiv
October 2024
Tuberculosis Research Section, Laboratory of Clinical Immunology and Microbiology, Division of Intramural Research, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD, USA.
Six months of chemotherapy using current agents is standard of care for pulmonary, drug-sensitive tuberculosis (TB), even though some are believed to be cured more rapidly and others require longer therapy. Understanding what factors determine the length of treatment required for durable cure in individual patients would allow individualization of treatment durations, provide better clinical tools to determine the of appropriate duration of new regimens, as well as reduce the cost of large Phase III studies to determine the optimal combinations to use in TB control programs. We conducted a randomized clinical trial in South Africa and China that recruited 704 participants with newly diagnosed, drug-sensitive pulmonary tuberculosis and stratified them based on radiographic disease characteristics as assessed by FDG PET/CT scan readers.
View Article and Find Full Text PDFBMC Health Serv Res
January 2025
Innovations & Grants, Stop TB Partnership, Global Health Campus - Chemin du Pommier 40, Le Grand-Saconnex, 1218, Geneva, Switzerland.
Introduction: In Pakistan, almost one-third of people who develop tuberculosis (TB) are missed by the National TB Program (NTP). A considerable number of people with TB receive treatment in the private sector but remain unnotified. This study documents the outcomes of an intervention to identify people with TB through private pharmacy engagement, building on mapping TB medicine sales in Punjab Province.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!